MRNA•Moderna raised its 2026 revenue growth outlook to 15%-25%, up from its original forecast of up to 10%. It expects strategic partnerships to drive most sales outside the U.S.
Moderna raised its 2026 revenue growth outlook to 15%-25%, exceeding its original forecast of up to 10%. Strategic partnerships are expected to drive the majority of sales outside the U.S., providing recurring revenue under multiyear agreements.
Moderna cited the mFLUSIVA launch, European product approvals and partnerships in Mexico and Taiwan as growth drivers for 2027.
